MetLife Investment Management LLC Purchases 4,577 Shares of Travere Therapeutics, Inc. $TVTX

MetLife Investment Management LLC increased its position in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 10.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 49,288 shares of the company’s stock after purchasing an additional 4,577 shares during the quarter. MetLife Investment Management LLC owned approximately 0.06% of Travere Therapeutics worth $883,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new stake in shares of Travere Therapeutics in the 4th quarter valued at about $31,000. Caitong International Asset Management Co. Ltd bought a new position in Travere Therapeutics in the 1st quarter valued at about $62,000. Gen Wealth Partners Inc bought a new position in Travere Therapeutics in the 4th quarter valued at about $73,000. KBC Group NV bought a new position in Travere Therapeutics in the 1st quarter valued at about $75,000. Finally, Twinbeech Capital LP bought a new position in Travere Therapeutics in the 4th quarter valued at about $177,000.

Analysts Set New Price Targets

TVTX has been the topic of several research analyst reports. Wall Street Zen raised shares of Travere Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, September 1st. Wedbush boosted their price target on Travere Therapeutics from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Thursday, August 7th. HC Wainwright restated a “buy” rating and issued a $47.00 price target on shares of Travere Therapeutics in a research note on Wednesday. Citigroup restated a “buy” rating on shares of Travere Therapeutics in a research note on Sunday, August 10th. Finally, Scotiabank restated an “outperform” rating on shares of Travere Therapeutics in a research note on Thursday, August 7th. Thirteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Travere Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $33.43.

Travere Therapeutics Stock Performance

Shares of NASDAQ:TVTX opened at $21.64 on Friday. The company’s 50 day moving average price is $16.83 and its two-hundred day moving average price is $17.35. Travere Therapeutics, Inc. has a 12-month low of $10.64 and a 12-month high of $25.29. The firm has a market cap of $1.93 billion, a PE ratio of -10.61 and a beta of 0.79. The company has a quick ratio of 1.98, a current ratio of 2.00 and a debt-to-equity ratio of 9.50.

Travere Therapeutics (NASDAQ:TVTX) last announced its earnings results on Wednesday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.14. Travere Therapeutics had a negative net margin of 50.64% and a negative return on equity of 717.68%. The firm had revenue of $94.84 million for the quarter, compared to analyst estimates of $100.18 million. During the same quarter in the prior year, the business posted ($0.65) EPS. The business’s revenue was up 111.5% compared to the same quarter last year. Equities research analysts predict that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current year.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.